207 EXPRESSION OF PYRUVATE DEHYDROGENASE KINASE-1 (PDK-1) AND DJ-1/PARK7 IN RENAL CELL CARCINOMA (RCC) AND ITS ASSOCIATION WITH PATHOLOGY AND OUTCOME

D. Baumunk(Klinikum Magdeburg), Steffen Weikert(St. Hedwig-Krankenhaus), Jan Ebbing(Charité - Universitätsmedizin Berlin), Martin Schostak(Aturo), Florian Jentzmik(Charité - Universitätsmedizin Berlin), Uta Reichelt(Charité - Universitätsmedizin Berlin), Kurt Miller(Charité - Universitätsmedizin Berlin)

The Journal of Urology

March 23, 2010

10.1016/j.juro.2010.02.264

Cited by 0

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

|New England Journal of Medicine|2014|3k

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

|The Lancet Oncology|2015|1.4k

The Epidemiology of Renal Cell Carcinoma

|European Urology|2011|1k

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

|European Urology|2016|414

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

|The Lancet Oncology|2016|218